Sydney, Australia, March 21, 2022 – (ABN newswire) – VGI Health Technology Limited (NSX: VTL) is pleased to announce that Dr. Jordan Moonmember of his Scientific Advisory Boardwill present a summary to American Society of Nutrition (ASN) Annual Conference, Nutrition 2022. In 2028, ASN will celebrate 100 years as a leading advocate for nutrition scientists and the advancement of nutrition. With thousands of members in over 100 countries, ASN Nutrition 2022 is the ideal platform for Dr Moon to discuss his work.
In association with the ASN, an abstract will be presented during the conference (June 14-16, 2022) entitled “Transmucosal delivery of tocotrienols from delta-tocotrienol powder: a multidose pharmacokinetic study”.
The abstract describes some of the results that were generated from a pharmacokinetic study conducted by Dr Moon in the United States using new formulations developed for the transmucosal delivery of tocotrienols. These new formulations and manufacturing methods are also the subject of a new patent application “PCT/AU2021/051449 – Transmucosal delivery of tocotrienols” made by the 100% subsidiary of VTL Invictus Biotechnology Pty Ltd to December 3, 2021. The data from this study supports the fact that there is more flexibility with dosages for this particular drug delivery platform than previous research data had suggested.
Sixteen healthy research subjects (m=8, f=8, 32 +/- 8 years, 171 +/- 7 cm, 81.6 +/- 13.8 kg) were randomly given 40 mg or 80 mg of a powder containing delta tocotrienol (DT3) on an empty stomach. The subjects were instructed to hold the powder under their tongue until it was completely dissolved.
Blood samples were taken at 0, 60, 90, 120, 180, 240, 360 and 480 minutes. The subjects received a meal consisting of carbohydrates, proteins and fats after four hours. DT3 concentrations were calculated from blood plasma using protein precipitation followed by liquid-liquid extraction.
Analytes were separated by liquid chromatography mass spectrometry (LCMS) with the extracts assayed against a standard curve. The bioavailability of DT3 was assessed using the parameters maximum plasma concentration (Cmax), time to reach maximum plasma concentration (Tmax) and total area under the plasma concentration-time curve (AUC).
The plasma concentration of DT3 reached 44.05 ng/ml (Cmax) for the 40mg group and reached 127.4 ng/ml (Cmax) (+83.4 ng/ml increase) for the 80mg group. Tmax was reached at 360 minutes for the 40 and 80 mg groups. The AUC for 40 mg was 9941.6 ng/ml*min, with a +2.9 fold increase seen in the 80 mg group (29072.2 ng/ml*min) compared to 40 mg.
Transmucosal administration of tocotrienols from a delta-tocotrienol powder containing 40 mg and 80 mg of DT3 resulted in a progressively high rate of absorption for both doses, with 80 mg appearing to increase total plasma DT3 by a difference +2.9 times that of a 40 mg dose. Doses of 40 and 80 mg of DT3 administered transmucosally showed increased plasma concentrations of DT3 in healthy men and women over a period of at least 8 hours.
Dr Moon said: “Our recent findings and data based on the novel formulations of the latest PCT patent application are very exciting as we have shown that the VTL delivery platform can accommodate a wide range of doses and that there appears to be a clear linear and predictable dose-response This creates a new opportunity for VTL to develop new products to add to its portfolio of pharmaceuticals and nutraceuticals”.
Dr Moon will soon begin the next phase of work on VTL’s DT3 transmucosal formulations, a multiple escalating dose pharmacokinetic study as well as a study evaluating various parameters of exercise performance and recovery.
About VGI Health Technology Limited:
VGI Health Technology Limited (NSX: VTL) is an Australian-listed biotechnology company that develops and markets novel dietary supplements and prescription medicines based on natural products (tocotrienols) that have broad therapeutic potential, including: delayed onset muscle pain , muscle recovery, exercise endurance, non-alcohol products Fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), pancreatic cancer, hyperlipidemia, hypertension and diabetes. VTL owns and controls patents and other intellectual property rights for novel approaches to the noninvasive delivery of tocotrienols directly to target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription drugs.
Glenn TongCEO and Managing Director
Phone. : +61 (0) 412 193 350
Andrew CrookInvestor Relations and Media
Phone. :+61 (0) 419 788 431
Catriona GloverCompany Secretary
Tel: +61 (0) 402 328 200
Copyright (C) 2022 ABN Newswire. All rights reserved., sources English press releases